Identification of Patients with Recurrent Epithelial Ovarian Cancer Who Will Benefit from More Than Three Lines of Chemotherapy
| العنوان: | Identification of Patients with Recurrent Epithelial Ovarian Cancer Who Will Benefit from More Than Three Lines of Chemotherapy |
|---|---|
| المؤلفون: | Hee Seung Kim, Jae Weon Kim, Hyun Hoon Chung, Ga Won Yim, Noh Hyun Park, Aeran Seol, Yong Sang Song, Se Ik Kim, Joo Yeon Chung, Maria Lee |
| المصدر: | Cancer Research and Treatment. 54:1219-1229 |
| بيانات النشر: | Korean Cancer Association, 2022. |
| سنة النشر: | 2022 |
| مصطلحات موضوعية: | Oncology, Cancer Research, medicine.medical_specialty, endocrine system diseases, medicine.medical_treatment, Carcinoma, Ovarian Epithelial, Pharmacotherapy, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Adverse effect, Retrospective Studies, Ovarian Neoplasms, Chemotherapy, business.industry, Hazard ratio, medicine.disease, Chemotherapy regimen, Progression-Free Survival, Confidence interval, Serous fluid, Female, Neoplasm Recurrence, Local, business, Progressive disease |
| الوصف: | Purpose This study aimed to identify patients who would benefit from third and subsequent lines of chemotherapy in recurrent epithelial ovarian cancer (EOC).Materials and Methods Recurrent EOC patients who received third, fourth, or fifth-line palliative chemotherapy were retrospectively analyzed. Patients’ survival outcomes were assessed according to chemotherapy lines. Based on the best objective response, patients were divided into good-response (stable disease or better) and poor response (progressive disease or those who died before response assessment) groups. Survival outcomes were compared between the two groups, and factors associated with chemotherapy responses were investigated.Results A total of 189 patients were evaluated. Ninety-four and 95 patients were identified as good and poor response group respectively, during the study period of 2008 to 2021. The poor response group showed significantly worse progression-free survival (median, 2.1 months vs. 9.7 months; p < 0.001) and overall survival (median, 5.0 months vs. 22.9 months; p < 0.001) compared with the good response group. In multivariate analysis adjusting for clinicopathologic factors, short treatment-free interval (TFI) (hazard ratio [HR], 5.557; 95% confidence interval [CI], 2.403 to 12.850), platinum-resistant EOC (HR, 2.367; 95% CI, 1.017 to 5.510), and non-serous/endometrioid histologic type (HR, 5.045; 95% CI, 1.152 to 22.088) were identified as independent risk factors for poor response. There was no difference in serious adverse events between good and poor response groups (p=0.167).Conclusion Third and subsequent lines of chemotherapy could be carefully considered for palliative purposes in recurrent EOC patients with serous or endometrioid histology, initial platinum sensitivity, and long TFIs from the previous chemotherapy regimen. |
| تدمد: | 2005-9256 1598-2998 |
| DOI: | 10.4143/crt.2021.1010 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::57370f30092db193debef9f566320a12 https://doi.org/10.4143/crt.2021.1010 |
| Rights: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....57370f30092db193debef9f566320a12 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 20059256 15982998 |
|---|---|
| DOI: | 10.4143/crt.2021.1010 |